Pre-Antiretroviral Therapy Serum Selenium Concentrations Predict WHO Stages 3, 4 or Death but not Virologic Failure Post-Antiretroviral Therapy.

Shivakoti, Rupak, Gupte, Nikhil, Yang, Wei-Teng, Mwelase, Noluthando, Kanyama, Cecilia, Tang, Alice M, Pillay, Sandy, Samaneka, Wadzanai, Riviere, Cynthia, Berendes, Sima, Lama, Javier R, Cardoso, Sandra W, Sugandhavesa, Patcharaphan, Semba, Richard D, Christian, Parul, Campbell, Thomas B and Gupta, Amita (2014) 'Pre-Antiretroviral Therapy Serum Selenium Concentrations Predict WHO Stages 3, 4 or Death but not Virologic Failure Post-Antiretroviral Therapy.'. Nutrients, Vol 6, Issue 11, pp. 5061-5078.

Preview

Text Nutrients_6_11_5061-5078.pdf - Published Version Available under License Creative Commons Attribution. Download (244kB)

Abstract

A case-cohort study, within a multi-country trial of antiretroviral therapy (ART) efficacy (Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS)), was conducted to determine if pre-ART serum selenium deficiency is independently associated with human immunodeficiency virus (HIV) disease progression after ART initiation. Cases were HIV-1 infected adults with either clinical failure (incident World Health Organization (WHO) stage 3, 4 or death by 96 weeks) or virologic failure by 24 months. Risk factors for serum selenium deficiency (<85 μg/L) pre-ART and its association with outcomes were examined. Median serum selenium concentration was 82.04 μg/L (Interquartile range (IQR): 57.28-99.89) and serum selenium deficiency was 53%, varying widely by country from 0% to 100%. In multivariable models, risk factors for serum selenium deficiency were country, previous tuberculosis, anemia, and elevated C-reactive protein. Serum selenium deficiency was not associated with either clinical failure or virologic failure in multivariable models. However, relative to people in the third quartile (74.86-95.10 μg/L) of serum selenium, we observed increased hazards (adjusted hazards ratio (HR): 3.50; 95% confidence intervals (CI): 1.30-9.42) of clinical failure but not virologic failure for people in the highest quartile. If future studies confirm this relationship of high serum selenium with increased clinical failure, a cautious approach to selenium supplementation might be needed, especially in HIV-infected populations with sufficient or unknown levels of selenium.

Item Type:	Article
Additional Information:	This article belongs to the Special Issue Dietary Selenium and Human Health
Subjects:	QU Biochemistry > Vitamins > QU 145 Nutrition. Nutritional requirements QV Pharmacology > QV 38 Drug action. WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503 Acquired immunodeficiency syndrome. HIV infections WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503.2 Therapy
Faculty: Department:	Clinical Sciences & International Health > International Public Health Department
Digital Object Identifer (DOI):	https://doi.org/10.3390/nu6115061
Depositing User:	Helen Fletcher
Date Deposited:	19 Dec 2014 10:55
Last Modified:	06 Feb 2018 13:08
URI:	https://archive.lstmed.ac.uk/id/eprint/4686

Statistics

View details

Actions (login required)

Edit Item